Version history

{
  "description": "Methodology challenge: dataset 'Allen Brain SEA-AD MTG 10x snRNA-seq' — evaluate design, statistical methods, and reproducibility.\n\n[TARGET_ARTIFACT type=dataset id=dataset-192467e0-fe96-43cb-a64f-e891cdcff111]\n[DEBATE_TYPE methodology_challenge]\n[PERSONAS provenance_auditor,bias_detector,schema_validator]\n[NUM_ROUNDS 4]\n[AUTO_TRIGGER rule=notebook_debate_scheduler]",
  "domain": "neurodegeneration",
  "status": "resolved",
  "priority_score": 0.92,
  "estimated_effort": "medium",
  "evidence_summary": "Resolved by hypothesis h-5b378bd3: TREM2-APOE Axis Dissociation for Selective DAM Activation. Score: 0.886. Supporting PMIDs: 28930663, 30617257.",
  "resolution_criteria": "Resolved when the provenance_auditor persona certifies the SEA-AD MTG 10x snRNA-seq dataset's cell isolation protocol, library preparation kit, sequencing platform, and computational pipeline (cell ranger vs outro), and the bias_detector persona identifies any batch effects, population stratification issues, or confounding variables. A passing assessment requires: (1) schema validation confirming metadata fields for donor age, sex, PMI, APOE status, clinical diagnosis, and brain region; (2) reproducibility audit confirming >=80% overlap between published marker gene lists (APP, MAPT, GFAP, CLU) and dataset's top 20 differentially expressed genes; (3) statistical methods review confirming appropriate multiple-testing correction (FDR < 0.05) and minimum biological replicate count (n >= 3 donors per group). The gap closes when a methodologist-signed artifact records these validations with quantitative thresholds and links to the source dataset in the KG.",
  "market_price": 0.5
}